At a glance
- Originator Jiangsu Hengrui Medicine Co.; Shanghai Institute of Materia Medica
- Developer Shanghai Institute of Materia Medica
- Class Antineoplastics; Indoles; Morpholines; Pyrroles; Small molecules
- Mechanism of Action Vascular endothelial growth factor receptor-2 antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours in China (PO, Tablet)
- 20 Dec 2012 Jiangsu Hengrui Medicine Co. terminates Phase-I trial in Solid tumours in China (NCT01416623)
- 01 Sep 2010 Phase-I clinical trials in Solid tumours in China (PO)